- Home
- IPHA vs CBUS Comparison
IPHA vs CBUS Comparison
Compare IPHA & CBUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IPHA | CBUS |
|---|---|---|
| Founded | 1999 | 2010 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 69.9M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | IPHA | CBUS |
|---|---|---|
| Price | $1.79 | $1.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | $5.00 | ★ $20.00 |
| AVG Volume (30 Days) | 24.2K | ★ 172.1K |
| Earning Date | 09-17-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $14,839,695.00 | $3,794,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | $109.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $1.09 |
| 52 Week High | $2.63 | $3.50 |
Technical Indicators
Market Signals| Indicator | IPHA | CBUS |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 63.07 |
| Support Level | $1.64 | $1.52 |
| Resistance Level | $1.94 | $1.75 |
| Average True Range (ATR) | 0.08 | 0.14 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 44.12 | 88.24 |
Price Performance
Historical ComparisonAbout IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About CBUS Cibus Inc.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.